Clopidogrel use in end-stage kidney disease

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• Clopidogrel, a P2Y12 inhibitor, prevents cardiovascular events but requires hepatic conversion and is subject to genetic variations affecting efficacy.
• Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are linked to clopidogrel resistance, with 50-80% of ESKD patients showing high residual platelet reactivity.
• Suboptimal outcomes post-coronary intervention in kidney disease patients may be due to clopidogrel resistance.

Purpose of the Study:

• To evaluate the efficacy and safety of clopidogrel in patients with end-stage kidney disease (ESKD).
• To investigate the role of platelet function assays in guiding clopidogrel therapy for ESKD patients.
• To explore alternative antiplatelet agents for ESKD patients with high on-treatment residual platelet reactivity.

Main Methods:

• Review of existing clinical trial data, including reanalysis of CURE and CREDO trials for CKD populations.
• Assessment of clopidogrel's association with adverse outcomes, including mortality and bleeding events, in ESKD patients.
• Discussion of the utility of various platelet reactivity assays in the context of ESKD treatment.

Main Results:

• Reanalysis of trials showed reduced or no benefit of clopidogrel in CKD patients (eGFR <60 ml/minute).
• ESKD patients were largely excluded from major clopidogrel trials, limiting evidence for their specific benefit.
• Clopidogrel use in ESKD is associated with increased risks of death, bleeding-related death, and hospitalization for bleeding.

Conclusions:

• Current evidence suggests ESKD patients may not benefit from clopidogrel as much as the general population and may experience harm.
• The effectiveness of platelet function assays in tailoring clopidogrel therapy for ESKD remains unclear.
• Further well-designed studies are required to establish clopidogrel's role in ESKD and evaluate alternatives like prasugrel and ticagrelor.